Modification of phosphorylation in tau-T231 or p-tau S396 may play a role in formation of NFT in the AD brain, whereas especially tau-S396-404 seems to be one of the earliest molecular targets in AD (Abraha et al., 2000; Gong and Iqbal, 2008; Hanger et al., 2009a; Mondragon-Rodriguez et al., 2014). The gene discussed is MAPT; the disease is Alzheimer disease.